2.2094
price up icon5.07%   0.1194
 
loading
Adagene Inc Adr stock is traded at $2.2094, with a volume of 928. It is up +5.07% in the last 24 hours and down -18.67% over the past month. Adagene Inc platform-driven, clinical-stage biopharmaceutical company engaged in transforming the discovery and development of novel antibody-based cancer immunotherapies. It is principally engaged in research, development and production of monoclonal antibody drugs for cancers. The company's platform is designed to generate therapeutic antibody candidates with functional epitopes and species cross-reactivity as highlighted by the company's immunotherapy pipeline.
See More
Previous Close:
$2.09
Open:
$2.15
24h Volume:
928
Relative Volume:
0.01
Market Cap:
$97.84M
Revenue:
$18.11M
Net Income/Loss:
$-18.95M
P/E Ratio:
-2.5616
EPS:
-0.8625
Net Cash Flow:
-
1W Performance:
-5.34%
1M Performance:
-18.67%
6M Performance:
-15.21%
1Y Performance:
+62.67%
1-Day Range:
Value
$2.15
$2.19
1-Week Range:
Value
$2.01
$2.4438
52-Week Range:
Value
$1.34
$4.38

Adagene Inc Adr Stock (ADAG) Company Profile

Name
Name
Adagene Inc Adr
Name
Phone
-
Name
Address
-
Name
Employee
174
Name
Twitter
Name
Next Earnings Date
2024-03-28
Name
Latest SEC Filings
Name
ADAG's Discussions on Twitter

Compare ADAG with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
ADAG 2.19 97.84M 18.11M -18.95M 0 -0.8625
VRTX 446.42 115.74B 10.63B -479.80M -1.35B 13.33
REGN 739.53 81.65B 13.85B 4.65B 3.32B 35.06
ARGX 587.24 34.86B 1.86B -40.29M -1.28B -4.16
ALNY 248.68 32.09B 2.09B -332.26M 16.06M -4.14
BNTX 102.48 24.49B 3.30B -501.07M 1.03B 11.54

Adagene Inc Adr Stock (ADAG) Upgrades & Downgrades

Date Action Analyst Rating Change
Jun-25-21 Initiated China Renaissance Buy
Mar-08-21 Initiated Goldman Buy
Mar-08-21 Initiated Jefferies Buy
Mar-08-21 Initiated Morgan Stanley Overweight

Adagene Inc Adr Stock (ADAG) Latest News

pulisher
Nov 20, 2024

Is Adagene (ADAG) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance

Nov 20, 2024
pulisher
Nov 20, 2024

Anheuser-Busch InBev S.A. ADR falls Monday, underperforms market - MSN

Nov 20, 2024
pulisher
Nov 20, 2024

Algorae Pharmaceuticals Streamlines Operations with OTCQB Exit - MSN

Nov 20, 2024
pulisher
Nov 13, 2024

Adagene Inc. (NASDAQ:ADAG) Sees Significant Decline in Short Interest - MarketBeat

Nov 13, 2024
pulisher
Nov 08, 2024

Anheuser-Busch InBev S.A. ADR falls Friday, underperforms market - MSN

Nov 08, 2024
pulisher
Nov 07, 2024

Adagene reports new findings at SITC meeting By Investing.com - Investing.com Canada

Nov 07, 2024
pulisher
Nov 07, 2024

Adagene reports new findings at SITC meeting - Investing.com India

Nov 07, 2024
pulisher
Nov 07, 2024

Adagene Presents Two Posters with New Insights on Increased Therapeutic Index for Masked Anti-CTLA-4 SAFEbody® ADG126 (Muzastotug) and Data Reinforcing Clinical Safety and Efficacy for ADG126 as Monotherapy and in Combination with Anti-PD-1 T - Wahanariau

Nov 07, 2024
pulisher
Nov 07, 2024

Adagene Presents Two Posters with New Insights on Increased - GlobeNewswire

Nov 07, 2024
pulisher
Nov 07, 2024

Adagene's ADG126 Shows Breakthrough Results in Cancer Treatment, Outperforms Ipilimumab | ADAG Stock News - StockTitan

Nov 07, 2024
pulisher
Oct 27, 2024

Short Interest in Adagene Inc. (NASDAQ:ADAG) Declines By 30.7% - MarketBeat

Oct 27, 2024
pulisher
Oct 11, 2024

Adagene Inc. (NASDAQ:ADAG) Short Interest Update - MarketBeat

Oct 11, 2024
pulisher
Oct 09, 2024

Adagene Announces Upcoming Poster Presentations on Masked Anti-CTLA-4 SAFEbody® ADG126 (Muzastotug) at Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting - The Manila Times

Oct 09, 2024
pulisher
Oct 09, 2024

Adagene Announces Upcoming Poster Presentations on Masked - GlobeNewswire

Oct 09, 2024
pulisher
Sep 28, 2024

Is DaVita (DVA) Stock Outpacing Its Medical Peers This Year? - MSN

Sep 28, 2024
pulisher
Sep 20, 2024

HC Wainwright Analysts Lift Earnings Estimates for Adagene Inc. (NASDAQ:ADAG) - MarketBeat

Sep 20, 2024
pulisher
Sep 20, 2024

Adagene Inc. to Post FY2024 Earnings of ($0.78) Per Share, HC Wainwright Forecasts (NASDAQ:ADAG) - Defense World

Sep 20, 2024
pulisher
Sep 20, 2024

Adagene stock holds Buy rating as ESMO data reinforces drug potential in MSS-CRC - Investing.com

Sep 20, 2024
pulisher
Sep 19, 2024

Adagene (NASDAQ:ADAG) Receives Buy Rating from HC Wainwright - Defense World

Sep 19, 2024
pulisher
Sep 19, 2024

Adagene stock holds Buy rating as ESMO data reinforces drug potential in MSS-CRC By Investing.com - Investing.com South Africa

Sep 19, 2024
pulisher
Sep 18, 2024

HC Wainwright Reiterates "Buy" Rating for Adagene (NASDAQ:ADAG) - MarketBeat

Sep 18, 2024
pulisher
Sep 16, 2024

Adagene reports promising cancer therapy results - Investing.com

Sep 16, 2024
pulisher
Sep 16, 2024

Adagene Presents Results at ESMO Congress that Show Best-in-Class Therapeutic Potential for Anti-CTLA-4 SAFEbody® ADG126 (Muzastotug) in Combination with KEYTRUDA® (Pembrolizumab) in Advanced/Metastatic Microsatellite-stable (MSS) Colorect - StockTitan

Sep 16, 2024
pulisher
Sep 11, 2024

Are Medical Stocks Lagging Adagene (ADAG) This Year? - Yahoo Finance

Sep 11, 2024
pulisher
Aug 29, 2024

Adagene to Participate in Investor Conferences in September - GlobeNewswire

Aug 29, 2024
pulisher
Aug 28, 2024

Adagene Inc. (NASDAQ:ADAG) Short Interest Up 170.8% in August - Defense World

Aug 28, 2024
pulisher
Aug 21, 2024

Liquidia (NASDAQ:LQDA) vs. Adagene (NASDAQ:ADAG) Critical Contrast - Defense World

Aug 21, 2024
pulisher
Aug 14, 2024

Adagene Inc. (NASDAQ:ADAG) Short Interest Down 34.2% in July - MarketBeat

Aug 14, 2024
pulisher
Aug 09, 2024

Is MannKind (MNKD) Stock Outpacing Its Medical Peers This Year? - MSN

Aug 09, 2024
pulisher
Jul 26, 2024

Short Interest in Adagene Inc. (NASDAQ:ADAG) Decreases By 62.9% - Defense World

Jul 26, 2024
pulisher
Jul 26, 2024

Adagene Reports Six Month Financial Results for 2024 and Provides Corporate Update - GlobeNewswire

Jul 26, 2024
pulisher
Jul 23, 2024

Head-To-Head Survey: Altimmune (NASDAQ:ALT) vs. Adagene (NASDAQ:ADAG) - Defense World

Jul 23, 2024
pulisher
Jul 22, 2024

Adagene (NASDAQ:ADAG) Rating Reiterated by HC Wainwright - MarketBeat

Jul 22, 2024
pulisher
Jul 13, 2024

Adagene Inc. (NASDAQ:ADAG) Short Interest Up 45.9% in June - Defense World

Jul 13, 2024
pulisher
Jul 12, 2024

Adagene Announces Poster Presentation on Masked Anti-CTLA-4 - GlobeNewswire

Jul 12, 2024
pulisher
Jul 12, 2024

Adagene Announces Poster Presentation on Masked Anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with Pembrolizumab in MSS CRC at Upcoming European Society for Medical Oncology (ESMO) Congress in September - Yahoo Finance

Jul 12, 2024
pulisher
Jul 08, 2024

Adagene To Participate In The SVB Leerink 11th Annual Global Healthcare Conference - Barchart

Jul 08, 2024
pulisher
Jul 07, 2024

Spruce Biosciences (NASDAQ:SPRB) and Adagene (NASDAQ:ADAG) Financial Contrast - Defense World

Jul 07, 2024
pulisher
Jul 02, 2024

Adagene Reports Full Year 2021 Financial Results and Provides Corporate Update - Quantisnow

Jul 02, 2024
pulisher
Jul 02, 2024

Adagene Announces Updates to its Board of Directors - Quantisnow

Jul 02, 2024
pulisher
Jul 02, 2024

Adagene Announces Authorization of Share Repurchase Program up to US$10 Million - Quantisnow

Jul 02, 2024
pulisher
Jul 02, 2024

Adagene Reports Full Year 2022 Financial Results and Provides Corporate Update - Quantisnow

Jul 02, 2024
pulisher
Jul 02, 2024

Adagene to Participate in the SVB Leerink 11th Annual Global Healthcare Conference - Quantisnow

Jul 02, 2024
pulisher
Jul 02, 2024

Adagene Reports Six Month Financial Results for 2023 and Provides Corporate Update - Quantisnow

Jul 02, 2024
pulisher
Jul 02, 2024

Adagene Presents Data Demonstrating First and Best-in-Class Potential for Differentiated Preclinical Antibody Candidates at American Association for Cancer Research (AACR) Annual Meeting 2022 - Quantisnow

Jul 02, 2024

Adagene Inc Adr Stock (ADAG) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$70.68
price down icon 0.42%
$18.62
price up icon 0.16%
$36.06
price down icon 1.68%
$364.60
price up icon 0.01%
$196.58
price up icon 0.88%
$102.64
price up icon 0.27%
Cap:     |  Volume (24h):